{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:44:24Z","timestamp":1782823464145,"version":"3.54.5"},"reference-count":32,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sanofi Romania"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the effectiveness and safety of insulin glargine and lixisenatide (iGlarLixi) fixed-ratio combination on a cohort of Romanian adults with type 2 diabetes (T2D).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Open-label, 24-week, prospective cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>65 secondary care diabetes centres in Romania.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>The study included 901 adults with T2D suboptimally controlled with previous oral antidiabetic drugs (OADs)\u00b1basal insulin (BI) who initiated treatment with iGlarLixi upon the decision of the investigator. Major exclusion criteria were iGlarLixi contraindications and refusal to participate. 876 subjects received at least one dose of iGlarLixi (intention-to-treat\/safety population).<\/jats:p><\/jats:sec><jats:sec><jats:title>Primary and secondary outcome measures<\/jats:title><jats:p>The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to week 24 in the modified intention-to-treat population (study participants with HbA1c available at baseline and week 24). Secondary efficacy outcomes were percentage of participants reaching HbA1c targets and change in fasting plasma glucose (FPG).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean baseline HbA1c was 9.2% (SD 1.4) and FPG was 10.8\u2009mmol\/L (2.9). Mean HbA1c change was \u22121.3% (95% CI: \u22121.4% to \u22121.2%, p&lt;0.0001) at week 24. HbA1c levels \u22646.5%, &lt;7%\u2009and&lt;7.5% at week 24 were achieved by 72 (8.9%), 183 (22.6%) and 342 (42.3%) participants, respectively. Mean FPG change was \u22123.1\u2009mmol\/L (95%\u2009CI: \u22123.3 to \u22122.8, p&lt;0.001) at week 24. Mean body weight change was \u22121.6\u2009kg (95%\u2009CI: \u22121.9 to \u22121.3, p&lt;0.001) at 24 weeks. Mean iGlarLixi dose increased from 19.5 U (SD 7.7) and 30.1 U (10.0) to 30.2 U (8.9) (ratio 2\/1 pen) and 45.0 U (11.6) (ratio 3\/1 pen). Adverse events (AEs) were reported by 43 (4.9%) participants (18 (2.1%) gastrointestinal) with 4 (0.5%) reporting serious AEs. 13 (1.5%) participants reported at least one event of symptomatic hypoglycaemia, with one episode of severe hypoglycaemia reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In a real-world setting, 24-week treatment with iGlarLixi provided a significant reduction of HbA1c with body weight loss and low hypoglycaemia risk in T2D suboptimally controlled with OADs\u00b1BI treatment.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2022-060852","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T14:46:32Z","timestamp":1653662792000},"page":"e060852","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro)"],"prefix":"10.1136","volume":"12","author":[{"given":"Cornelia","family":"Bala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Cerghizan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan-Mircea","family":"Mihai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Moise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Guja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"2022063010173903000_12.5.e060852.1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S002"},{"key":"2022063010173903000_12.5.e060852.2","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1962"},{"key":"2022063010173903000_12.5.e060852.3","unstructured":"International Diabetes Federation . IDF diabetes atlas. 9th edn. Brussels, Belgium: International Diabetes Federation, 2019."},{"key":"2022063010173903000_12.5.e060852.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"2022063010173903000_12.5.e060852.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4065-6"},{"key":"2022063010173903000_12.5.e060852.6","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00125-021-05539-8","article-title":"The legacy effect in diabetes: are there long-term benefits?","volume":"64","author":"Folz","year":"2021","journal-title":"Diabetologia"},{"key":"2022063010173903000_12.5.e060852.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa2032271"},{"key":"2022063010173903000_12.5.e060852.8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00125-019-05078-3","article-title":"Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS)","volume":"63","author":"Aschner","year":"2020","journal-title":"Diabetologia"},{"key":"2022063010173903000_12.5.e060852.9","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S009"},{"key":"2022063010173903000_12.5.e060852.10","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"2022063010173903000_12.5.e060852.11","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/j.dsx.2019.05.001","article-title":"Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: a critical appraisal","volume":"13","author":"Hernando","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"2022063010173903000_12.5.e060852.12","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0116"},{"key":"2022063010173903000_12.5.e060852.13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5"},{"key":"2022063010173903000_12.5.e060852.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0016-2"},{"key":"2022063010173903000_12.5.e060852.15","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1974"},{"key":"2022063010173903000_12.5.e060852.16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12325-018-0868-9","article-title":"Optimizing fixed-ratio combination therapy in type 2 diabetes","volume":"36","author":"Perreault","year":"2019","journal-title":"Adv Ther"},{"key":"2022063010173903000_12.5.e060852.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108478","article-title":"Titratable fixed-ratio combination of insulin glargine plus lixisenatide: a simplified approach to glycemic control in type 2 diabetes mellitus","volume":"170","author":"Giorgino","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"2022063010173903000_12.5.e060852.18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s13300-020-00777-2","article-title":"Expert opinion on the therapeutic use of the fixed-ratio combination of insulin glargine 100 U\/mL and Lixisenatide: a Central\/Eastern European perspective","volume":"11","author":"Haluz\u00edk","year":"2020","journal-title":"Diabetes Ther"},{"key":"2022063010173903000_12.5.e060852.19","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"2022063010173903000_12.5.e060852.20","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"2022063010173903000_12.5.e060852.21","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1357"},{"key":"2022063010173903000_12.5.e060852.22","doi-asserted-by":"crossref","DOI":"10.2337\/dc21-0393","article-title":"Advancing therapy in Suboptimally controlled basal insulin-treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial","author":"Rosenstock","year":"2021","journal-title":"Diabetes Care"},{"key":"2022063010173903000_12.5.e060852.23"},{"key":"2022063010173903000_12.5.e060852.24","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12297"},{"key":"2022063010173903000_12.5.e060852.25","first-page":"409","article-title":"Clinical and therapeutic characteristics of patients with type 2 diabetes mellitus in Romania \u2013 mentor study","volume":"25","author":"Serafinceanu","year":"2018","journal-title":"Rom J Diabetes Nutr Metab Dis"},{"key":"2022063010173903000_12.5.e060852.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2022063010173903000_12.5.e060852.27","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1111\/dom.13791","article-title":"Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial","volume":"21","author":"Davies","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2022063010173903000_12.5.e060852.28","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12096"},{"key":"2022063010173903000_12.5.e060852.29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2337\/db21-110-LB","article-title":"110-LB: efficacy, safety, and appropriateness of iGlarLixi, a fixed-ratio combination (FRC) in type 2 diabetes (T2D) in real-world settings: results from the ensure study","volume":"70","author":"Candido","year":"2021","journal-title":"Diabetes"},{"key":"2022063010173903000_12.5.e060852.30","doi-asserted-by":"publisher","DOI":"10.2337\/db21-637-P"},{"key":"2022063010173903000_12.5.e060852.31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/14740338.2021.1978974","article-title":"An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus","volume":"21","author":"Novodvorsk\u00fd","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"2022063010173903000_12.5.e060852.32","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s13300-020-00872-4","article-title":"Persistence with IDegLira in patients in clinical practice: a nationwide observational study in Sweden","volume":"11","author":"Eliasson","year":"2020","journal-title":"Diabetes Ther"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-060852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T17:45:26Z","timestamp":1656611126000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-060852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,27]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/bmjopen-2022-060852"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-060852","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}